Cara Therapeutics announces 'positive' top-line data from the adaptive Phase 2/3 trial of I.V. CR845 in patients undergoing abdominal surgeries
At the 1.0 mcg/kg dose, I.V. CR845 demonstrated statistically significant reductions in pain intensity compared to placebo at all pre-specified post-operative periods of 0-6 hours (p=0.001); 0-12 hours (p=0.004); 0-18 hours (p=0.013); and 0-24 hours (p=0.032). Additionally, I.V. CR845 treatment resulted in statistically significant reductions in the incidence of post-operative nausea and vomiting over the 24-hour period post-surgery for both 0.5 and 1.0 mcg/kg doses .
- The full results of this trial will be presented at a future scientific or medical conference.
No comments:
Post a Comment